Insights into the malfunctioning of the mitochondrial citrate carrier: Implications for cell pathology.

Autoimmune diseases Cancer Congenital diseases Inflammation Metabolic alterations Mitochondrial carrier family

Journal

Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730

Informations de publication

Date de publication:
08 2023
Historique:
received: 03 04 2023
revised: 08 05 2023
accepted: 12 05 2023
medline: 5 6 2023
pubmed: 21 5 2023
entrez: 20 5 2023
Statut: ppublish

Résumé

The mitochondrial citrate carrier (CIC) is a member of the mitochondrial carrier family and is responsible for the transit of tricarboxylates and dicarboxylates across the inner membrane. By modulating the flux of these molecules, it represents the molecular link between catabolic and anabolic reactions that take place in distinct cellular sub-compartments. Therefore, this transport protein represents an important element of investigation both in physiology and in pathology. In this review we critically analyze the involvement of the mitochondrial CIC in several human pathologies, which can be divided into two subgroups, one characterized by a decrease and the other by an increase in the flux of citrate across the inner mitochondrial membrane. In particular, a decrease in the activity of the mitochondrial CIC is responsible for several congenital diseases of different severity, which are also characterized by the increase in urinary levels of L-2- and D-2-hydroxyglutaric acids. On the other hand, an increase in the activity of the mitochondrial CIC is involved, in various ways, in the onset of inflammation, autoimmune diseases, and cancer. Then, understanding the role of CIC and the mechanisms driving the flux of metabolic intermediates between mitochondria and cytosol would potentially allow for manipulation and control of metabolism in pathological conditions.

Identifiants

pubmed: 37209873
pii: S0925-4439(23)00124-2
doi: 10.1016/j.bbadis.2023.166758
pii:
doi:

Substances chimiques

citrate-binding transport protein 0
Carrier Proteins 0
Citric Acid 2968PHW8QP

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

166758

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Vincenzo Zara (V)

Department of Biological and Environmental Sciences and Technologies, University of Salento, I-73100 Lecce, Italy.

Graziana Assalve (G)

Department of Biological and Environmental Sciences and Technologies, University of Salento, I-73100 Lecce, Italy.

Alessandra Ferramosca (A)

Department of Biological and Environmental Sciences and Technologies, University of Salento, I-73100 Lecce, Italy. Electronic address: alessandra.ferramosca@unisalento.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH